Page 15 - Arthurm Fishberg News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Icahn School of Medicine at Mount Sinai Receives NIH Award to Promote Inclusive Excellence in Biomedical Sciences | Mount Sinai
mountsinai.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mountsinai.org Daily Mail and Mail on Sunday newspapers.
Investegate |Renalytix PLC Announcements | Renalytix PLC: Directorate Change
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Investegate |Verici Dx PLC Announcements | Verici Dx PLC: Non-executive Director receives award
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
IMAGE: Synergy Scores
Mount Sinai Health System
A combination of remdesivir, a drug currently approved in the United States for treating COVID-19 patients, and repurposed drugs for hepatitis C virus (HCV) was 10 times more effective at inhibiting SARS-CoV-2, the virus that causes COVID-19.
The combination therapy points a way toward a treatment for unvaccinated people who become infected, as well as for vaccinated people whose immunity has waned, for example due to the emergence of virus variants that escape this immune protection.
Four HCV drugs simeprevir, vaniprevir, paritaprevir, and grazoprevir in combination with remdesivir boosted the efficacy of remdesivir by as much as 10-fold, the researchers reported today in
Effect of COVID-19 Antiviral Remdesivir Multiplied 10-Fold by Hepatitis C Drugs Effect of COVID-19 Antiviral Remdesivir Multiplied 10-Fold by Hepatitis C Drugs
Drugs used to treat hepatitis C render remdesivir 10 times better at inhibiting the coronavirus in cell cultures. [Jenna Luecke/University of Texas at Austin]
April 27, 2021
Share
Remdesivir, the only antiviral drug approved in the United States for treating COVID-19 patients, is up to 10 times more effective when it is mixed with a repurposed hepatitis C drug. The effect has been observed with several hepatitis C drugs namely, simeprevir, grazoprevir, paritaprevir, and vaniprevir. All four appear to have the same remdesivir-boosting mechanism: inhibition of the SARS-CoV-2 papain-like protease (PL